ImmunoBrain
Ness Ziona · Founded 2015
About ImmunoBrain
ImmunoBrain is a clinical stage biopharmaceutical company transforming the fight against neurodegeneration and aging by targeting the immune system, restoring brain immune communications and boosting natural repair mechanisms. ImmunoBrain’s lead program is a proprietary antibody targeting the inhibitory immune checkpoint pathway PD-1/PD-L1, to treat Alzheimer's disease. ImmunoBrain's novel approach for the treatment of neurodegeneration is based on years of innovative, cutting-edge scientific discoveries made in the lab of Prof. Michal Schwartz at the Weizmann Institute of Science.
Company Facts
- Founded: 2015
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $6.5M
- Last round: Grant (Aug 2021)
- Website: https://immunobrain.com/
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/immunobrain-69060 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.